The vaccine “Grippol® Quadrivalent” was registered in Russia in 2018, the drug is produced in Russia using the technology of a full production cycle of the finished dosage form (FDF) in accordance with GMP standards at the company’s own enterprise. This influenza vaccine protects against 4 strains: 2 type A viruses (H1N1 and H3N2) and 2 lines of type B virus (B/Yamagata + B/Victoria). The azoximer adjuvant bromide, which is part of it, reduces the amount of antigens in the vaccine by a factor of three and provides a pronounced humoral and cellular immune response, which is confirmed by scientific publications in the international peer-reviewed journals Frontiers in Immunology, Vaccine and others.
“Grippol® Quadrivalent” was developed according to the technology for the production of vaccines of the “Grippol®” family, which are included in the state immunization programs of a number of countries, have a broad evidence base and many years of experience in use. The creation and supply of the vaccine is in line with the implementation of the National Strategy for the Development of Immunoprophylaxis of Infectious Diseases for the period up to 2035, within the framework of which Russia approved a plan for the transition to the use of quadrivalent vaccines for the prevention of influenza for the period 2021-2025.
“Maintaining and strengthening the immunity of citizens is one of the key activities of the company. Deliveries of the modern vaccine Grippol® Quadrivalent not only open up additional opportunities for protecting Russian patients from the influenza virus, but also expand the company’s export potential,” said Mikhail Grubman, Managing Director of Petrovax Pharm’s biotechnology business.
Since 2012, WHO has recommended the use of quadrivalent vaccines as the most effective tool in the fight against influenza. All influenza vaccines used for immunization in the United States in recent years, including those used in the pediatric segment, are quadrivalent. Most EU countries also use predominantly quadrivalent vaccines.
According to experts, vaccination should be 2-3 weeks before the start of an increase in the incidence of influenza, the optimal period for vaccination is from September to November. During the COVID-19 pandemic, influenza vaccination is part of the prevention of seasonal respiratory viral infections and reduces the risk of infection and severe illness.
Petrovax is the largest exporter of anti-influenza vaccines, the company has been supplying the trivalent vaccine Grippol® plus to the Russian and foreign markets for over 14 years, and this year its supply will exceed 12.5 million doses.